Management of hyperglycemia in type 2 diabetes: Evidence and uncertainty

Katherine Esposito, Sandro Gentile, Riccardo Candido, Alberto De Micheli, Marco Gallo, Gerardo Medea, Antonio Ceriello

Research output: Contribution to journalArticlepeer-review

Abstract

The panoply of treatment algorithms, periodically released to improve guidance, is one mean to face therapeutic uncertainty in pharmacological management of hyperglycemia in type 2 diabetes, especially after metformin failure. Failure of recent guidelines to give advice on the use of specific antidiabetic drugs in patients with co-morbidity may generate further uncertainty, given the frequent association of type 2 diabetes with common comorbidity, including, although not limited to obesity, cardiovascular disease, impaired renal function, and frailty. The Italian Association of Diabetologists (Associazione Medici Diabetologi, AMD) recognized the need to develop personalized treatment plans for people with type 2 diabetes, taking into account the patients' individual profile (phenotype), with the objective of the safest possible glycemic control. As not every subject with type 2 diabetes benefits from intensive glycemic control, flexible regimens of treatment with diabetes drugs (including insulin) are needed for reaching individualized glycemic goals. Whether personalized diabetology will improve the quality healthcare practice of diabetes management is unknown, but specific research has been launched.

Original languageEnglish
Article number81
JournalCardiovascular Diabetology
Volume12
Issue number1
DOIs
Publication statusPublished - May 30 2013

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Fingerprint Dive into the research topics of 'Management of hyperglycemia in type 2 diabetes: Evidence and uncertainty'. Together they form a unique fingerprint.

Cite this